Although few studies are correlating the action of either G9a/GLP or GLP blocking separately with ALL, the data we have so far indicates that control of the G9a/GLP pathway represents a potential treatment for ALL [103]. This evidence concerns the gene EHMT2 and acute lymphoblastic leukemia.